相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Early Growth Retardation and Insulin Resistance in JAZF1 KO Mice
Hui-Young Lee et al.
DIABETES (2011)
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Add-on therapies to metformin for type 2 diabetes
Mansur Shomali
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors
Vincent Mascitti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Michael J. Jurczak et al.
DIABETES (2011)
Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study
Elizabeth K. Hussey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
Elizabeth K. Hussey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents
William N. Washburn
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 2
William N. Washburn
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
George L. Bakris et al.
KIDNEY INTERNATIONAL (2009)
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus
Kjeld Hermansen et al.
DRUG SAFETY (2007)
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
Kenji Katsuno et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats
Yuka Fujimoto et al.
DIABETES (2006)
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy - A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
D. M. Nathan et al.
DIABETOLOGIA (2006)
Diabetes and obesity: the twin epidemics
S Smyth et al.
NATURE MEDICINE (2006)
Insulin Treatment and Weight Gain in Type 2 Diabetes: Is Our Knowledge Complete?
Miriam Ryan et al.
CURRENT NUTRITION & FOOD SCIENCE (2006)
Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats
K Ueta et al.
LIFE SCIENCES (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
The sodium/glucose cotransport family SLC5
EM Wright et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2004)
Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997
DG Manuel et al.
DIABETES CARE (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure
RW Nesto et al.
DIABETES CARE (2004)
The relationship of postprandial glucose to HbA1c
R Landgraf
DIABETES-METABOLISM RESEARCH AND REVIEWS (2004)
Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats
K Nunoi et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2002)
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095
K Arakawa et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Risk factors for symptomatic urinary tract infection in women with diabetes
SE Geerlings et al.
DIABETES CARE (2000)
Antidiabetic effect of T-1095, an inhibitor of Na+-glucose cotransporter, in neonatally streptozotocin-treated rats
A Oku et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
分享论文
